76 terminated. 76 Phase 2, 12 Phase 3, 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 76 | Terminated 76 |
| Phase 3 | 12 | Terminated 12 |
| Phase 1 | 10 | Terminated 10 |
Follow Heart Failure: new trials by email Literature Review of Heart Failure trials Research Report on Heart Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy Carvedilol, Empagliflozin - HER2-positive Breast Cancer, HER2+ Breast Cancer | Phase 2 | Terminated | Washington University School of Medicine | 7 | 2025-04-16 | 2026-05-13 |
| REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction REGN5381, Placebo - Heart Failure | Phase 2 | Terminated | Regeneron Pharmaceuticals | 89 | 2024-04-11 | 2026-01-14 |
| A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure Placebo, XXB750 Low dose, XXB750 Medium Dose - Heart Failure | Phase 2 | Terminated | Novartis Pharmaceuticals | 136 | 2023-12-12 | 2026-01-27 |
| Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy Mycophenolate Mofetil, Prednisolone, Mycophenolate Mofetil Placebo - Inflammatory Cardiomyopathy | Phase 2 / Phase 3 | Terminated | LMU Klinikum | 9 | 2023-03-28 | 2025-07-25 |
| A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) LY3540378, Placebo - Heart Failure, Heart Failure With Preserved Ejection Fraction | Phase 2 | Terminated | Eli Lilly and Company | 332 | 2023-02-03 | 2026-02-05 |
| A Study of Ponsegromab in People With Heart Failure Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose - Heart Failure | Phase 2 | Terminated | Pfizer | 455 | 2022-09-26 | 2026-03-18 |
| Colchicine in HFpEF Colchicine, Placebo - Heart Failure, Inflammation | Phase 2 | Terminated | Montreal Heart Institute | 14 | 2022-06-17 | 2023-04-26 |
| Effectiveness of CRD-740 in Heart Failure CRD-740, Placebo - Heart Failure, Heart Failure With Reduced Ejection Fraction | Phase 2 | Terminated | Cardurion Pharmaceuticals, Inc. | 60 | 2022-05-26 | 2024-12-19 |
| COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction Colchicine - Myocardial Infarction, Acute | Phase 2 / Phase 3 | Terminated | University Hospital, Montpellier | 54 | 2020-12-04 | 2026-06-12 |
| Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects PL-3994 Aqueous Intravenous Solution Dose Ascention, PL-3994 Aqueous Intravenous Solution Single Dose - Heart Failure With Preserved Ejection Fraction | Phase 2 | Terminated | Palatin Technologies, Inc | 15 | 2020-11-12 | 2025-12-15 |
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
| Ozone Therapy in Refractory Ischemic Heart Disease. Ozone, Oxygen - Ischemic Heart Disease | Phase 2 / Phase 3 | Terminated | Bernardino Clavo, MD, PhD | 1 | 2020-02-26 | 2022-04-04 |
| Metformin in Heart Failure Without Diabetes Metformin hydrochloride, Placebo - Heart Failure | Phase 2 | Terminated | Columbia University | 6 | 2019-02-15 | 2024-07-18 |
| Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD Omega 3 fatty acids, Placebo - Heart Failure, Gastrointestinal Bleeding | Phase 1 / Phase 2 | Terminated | University of Chicago | 35 | 2019-01-23 | 2021-07-13 |
| Safety and Tolerability Study of AZD4831 in Patients With Heart Failure. AZD4831, Placebo - Heart Failure | Phase 2 | Terminated | AstraZeneca | 41 | 2018-12-11 | 2021-07-19 |
| Insulin Treatment in Diabetic Older People With Heart Failure. Insulin - Heart Failure, Diabetes Mellitus, Type 2 | Phase 2 | Terminated | Mario Negri Institute for Pharmacological Research | 10 | 2018-11-08 | 2019-11-18 |
| The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects Nicotinamide Riboside - Heart Failure | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 2 | 2018-09-27 | 2020-10-28 |
| Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure Sodium Zirconium Cyclosilicate, Placebo - Heart Failure | Phase 2 | Terminated | AstraZeneca | 182 | 2018-06-26 | 2021-06-15 |
| Effect of Dietary Nitrate Ingestion in Heart Failure Nitrate-rich Beetroot Juice, Nitrate-deplete Beetroot Juice - Heart Failure, Heart Failure, Systolic | Phase 2 | Terminated | Queen Mary University of London | 2 | 2018-06-01 | 2025-08-03 |
| Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload sc2Wear Furosemide Infusor - Heart Failure | Phase 2 / Phase 3 | Terminated | Steward St. Elizabeth's Medical Center of Boston, Inc. | 9 | 2018-04-05 | 2022-10-13 |
Showing 20 of 76. Sign in to see all of them.
Heart Diseases (8) · Cardiomyopathies (5) · Cardiovascular Diseases (5) · Renal Insufficiency (5) · Heart Failure, Diastolic (4) · Myocardial Infarction (4) · Breast Neoplasms (3) · Cardio-Renal Syndrome (3) · Diabetes Mellitus (3) · Hypertension (3) · Cardiomyopathy, Hypertrophic (2) · Cardiomyopathy, Hypertrophic, Familial (2) · Diabetes Mellitus, Type 2 (2) · Dyspnea (2)
Cardiovascular Diseases (71) · Heart Diseases (68) · Pathological Conditions, Signs and Symptoms (15) · Vascular Diseases (11) · Pathologic Processes (10) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Kidney Diseases (7) · Male Urogenital Diseases (7) · Urogenital Diseases (7) · Urologic Diseases (7) · Respiratory Tract Diseases (6) · Metabolic Diseases (5) · Myocardial Ischemia (5)
BAY 58-2667 (4) · Natriuretic Peptide, Brain (3) · Cardiac Resynchronization Therapy (2) · Colchicine (2) · Testosterone (2) · alagebrium (2) · empagliflozin (2) · 3,5-diiodothyropropionic acid (1) · AZD4831 (1) · Amlodipine (1) · Ascorbic Acid (1) · BG 9928 (1) · Bisoprolol (1) · Blood Specimen Collection (1) · Carnitine (1)
Bayer (4) · AstraZeneca (2) · Columbia University (2) · Harvest Technologies (2) · Novartis Pharmaceuticals (2) · University of Chicago (2) · AHEPA University Hospital (1) · Adrian Hernandez (1) · Assistance Publique - Hôpitaux de Paris (1) · Barnes-Jewish Hospital (1) · Bernardino Clavo, MD, PhD (1) · Biogen (1) · Biotronik, Inc. (1) · Capricor Inc. (1) · Cardiovascular Clinical Sciences Inc (1)
United States (51) · Canada (16) · Germany (12) · Poland (11) · United Kingdom (11) · Spain (10) · France (9) · Italy (9) · Czechia (8) · Hungary (8) · Israel (8) · Netherlands (7) · Belgium (6) · Australia (5) · Japan (5)
Bertram Pitt, MD (2) · Yoshifumi Naka, MD (2) · Adrian Hernandez, MD (1) · Alan Moskowitz, MD (1) · Allen Anderson, MD (1) · Amit Patel, MD (1) · Anitha Vijayan, M.D. (1) · Ann Nguyen, MD (1) · Antonio Abbate, M.D. (1) · Arnold Jacobson, MD (1) · Barry Fine, MD (1) · Benjamin JW Chow, MD, FRCPC (1) · Bernardino Clavo, MD, PhD (1)
PMID 19460848, PMID 20522572, PMID 22713287, PMID 22778174, PMID 23137493, PMID 23883653, PMID 23998714, PMID 25965717, PMID 27282848, PMID 28393439, PMID 29566816, PMID 29807890, PMID 32749459, PMID 34233913, PMID 36564955, PMID 37072105, PMID 38289979, PMID 40887551, PMID 41171251, PMID 41912806
2023 (4), 2009 (3), 2018 (2), P50HL077096 (2), 2016 (1), R01HL080152 (1), RC3HL103356-01 (1), U10HL084904 (1)